Atea Pharmaceuticals, Inc. AVIR 深 沪
等待开盘 07-02 09:30:00 美东时间
4.78
+0.130
+2.80%
华盛通- 最 高4.785
- 今 开4.68
- 成交量 47.26万股
- 最 低 4.625
- 昨 收 4.65
- 总市值 3.83亿
- 52周最高 6.45
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 2.78
- 委 比 -96.26%
- 总股本 8002.71万
- 历史最高 94.174
- 量 比 0.88
- 振 幅 3.44%
- 历史最低 2.455
- 每 手 1
- 风险率 0.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Atea Pharma Completes Patient Enrollment In C-FORWARD, Phase 3 Clinical Trial Outside North America, Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus Infection
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for the Treatment of HCV BOSTON...
06-25 19:08
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals announced the completion of patient enrollment in its Phase 3 C-FORWARD trial, evaluating the BEM/RZR regimen for treating hepatitis C virus (HCV) in over 880 treatment-naïve patients across 17 countries outside North America. Topline results are expected by year-end 2026. C-FORWARD and C-BEYOND represent the first global Phase 3 head-to-head trials of direct-acting antivirals for HCV. The trials aim to advance the standard o...
06-25 11:00
Seer Files Definitive Proxy Materials and Mails Letter to Stockholders
Seer, Inc. has filed definitive proxy materials for its 2026 Annual Meeting of Stockholders, urging shareholders to vote for its seven highly qualified director nominees on the BLUE proxy card. The company highlights its clear strategy to build the market for deep, unbiased proteomics, disciplined financial management, and the strong qualifications of its Board of Directors. Seer strongly opposes Bradley Radoff and Michael Torok’s proxy fight, ar...
06-03 22:00
BRIEF-Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-In-Class Profile Of The Regimen Of Bemnifosbuvir And Ruzasvir For The Treatment Of Hepatitis C Virus At Easl Congress 2026
BRIEF-Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-In-Class Profile Of The Regimen Of Bemnifosbuvir And Ruzasvir For The Treatment Of Hepatitis C Virus At Easl Congress 2026 May 27 (Reuters) - Atea Pharmaceuticals Inc AVIR.O : ATEA PHARMACEUTICALS PRESENT
05-27 21:30
Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
Atea Pharmaceuticals (NASDAQ:AVIR) held its first-quarter earnings conference c...
05-13 05:17
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
Atea Pharmaceuticals will host a live conference call and webcast on May 12, 2026, at 4:30 p.m. ET to discuss Q1 2026 financial results and provide a business update. Participants can join via phone using conference ID 13759581 or access the webcast at ir.ateapharma.com. The company focuses on developing oral antiviral therapies for serious viral diseases, with a pipeline targeting ssRNA viruses. An archived webcast will be available on Atea’s we...
05-05 11:00
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
Momentum warning for health care sector stocks: RSI indicator shows overbought assets. Arcellx (ACLX) and Atea Pharma (AVIR) among top-ranked.
03-18 20:59
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
